MENU
DE | EUR
-
-
-
-
- Forum Labo 2025
- Advanced Therapies Week (ATW) 2025
- SLAS Europe 2025
- Bioprocessing Summit Europe 2025
- Medlab Middle East 2025
- SLAS International 2025
- Biologics World Nordics 2025
- ASIA LABEX: The Lab Show 2025
- BioProcess International Europe 2025
- ISEV 2025
- Future Labs Live 2025
- DataHow Symposium 2025
- Cell 2025
-
-
-
-
- Forum Labo 2025
- Advanced Therapies Week (ATW) 2025
- SLAS Europe 2025
- Bioprocessing Summit Europe 2025
- Medlab Middle East 2025
- SLAS International 2025
- Biologics World Nordics 2025
- ASIA LABEX: The Lab Show 2025
- BioProcess International Europe 2025
- ISEV 2025
- Future Labs Live 2025
- DataHow Symposium 2025
- Cell 2025
DE | EUR
-
- Benchtop Centrifuges
- Floor-Standing Centrifuges
- Refrigerated Centrifuges
- Microcentrifuges
- Multipurpose Centrifuges
- High-Speed Centrifuges
- Ultracentrifuges
- Concentrator
- IVD Products
- High-Speed and Ultracentrifuge Consumables
- Centrifuge Tubes
- Centrifuge Plates
- Device Management Software
- Sample and Information Management
No results found
Search Suggestions

Vaccine Research Discovered
Well thought-out tools for pharmaceutical and biotech laboratories
Read more
Read less
THE MOST NOVEL VACCINES
Nucleic acid vaccines
Nucleic acid vaccines are made up of mRNA or plasmid DNA encoding viral antigenic components to express specific proteins of a pathogen after injection. The technology of mRNA vaccines made its breakthrough with SARS-CoV-2. With dozens of new applications including HIV, cancer, shingles, flu, cardiovascular applications, or Zika, it is a very promising technology.
Nucleic acid vaccines are made up of mRNA or plasmid DNA encoding viral antigenic components to express specific proteins of a pathogen after injection. The technology of mRNA vaccines made its breakthrough with SARS-CoV-2. With dozens of new applications including HIV, cancer, shingles, flu, cardiovascular applications, or Zika, it is a very promising technology.
Read more
Read less
➕ Multiple advantages such as exceptionally fast modifiability in response to mutations, high versatility, high safety, and a fast, cost-efficient, and scalable production in a cell-free system. Vaccines for multiple indications can be produced using the same process.
➖ During vaccination the mRNA must be delivered directly into cells, which requires specific injection devices, electroporation, or a carrier molecule. mRNA vaccines exhibit instability and require a cold chain
➖ During vaccination the mRNA must be delivered directly into cells, which requires specific injection devices, electroporation, or a carrier molecule. mRNA vaccines exhibit instability and require a cold chain
Read more
Read less
BETTER MRNA VACCINE DEVELOPMENT
Read more
Read less

*All products are for Research Use Only (RUO).
Read more
Read less
Read more
Read less